Physician profile
Rene Kahn
NPI 1154861599
$357,277.69
in general payments reported to CMS, 2019-2025
7 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $105K · 2021: $51K · 2022: $51K · 2023: $32K · 2024: $26K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $81K · Travel and Lodging: $5,414 · Food and Beverage: $1,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $80,918.00 |
| Travel and Lodging | $5,414.17 |
| Food and Beverage | $1,901.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $304,922.95 | 2019-2025 | Lybalvi, Aristada |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20,197.02 | 2019-2021 | |
| Boehringer Ingelheim International Gmbh | $12,337.59 | 2025 | |
| Merck Sharp & Dohme LLC | $7,676.06 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $6,235.75 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $5,888.23 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $20.09 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rene Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.